All
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Orano, Sanofi
Sanofi and Orano Med link for radioligand therapy development
Sanofi and Orano Group subsidiary Orano Med have announced a partnership to enhance the development of next-generation radioligand therapies (RLTs) for rare cancers. The companies plan to invest in a new entity,
SNY Inks Deal With Orano Med for Next-Generation Radioligand Therapies
Sanofi SNY announced that it has entered into an agreement with France-based cancer biotech Orano Med to jointly develop next-generation radioligand therapies for treating rare cancers.Radioligand therapy is a type of precision cancer treatment that combines a targeting compound (ligand) with a therapeutic radioisotope (a radioactive particle).
Sanofi invests €300m in Orano Med's lead-based radioligands
The transaction builds on a three-way partnership between Sanofi, Orano Med, and RadioMedix – signed in September with a €100 million upfront payment – to develop a radioligand therapy (RLT) for rare neuroendocrine tumours (NETs) called AlphaMedix (212Pb-dotamtate).
Sanofi returns to Orano with €300M for radioligand 'pioneer' project
Weeks after penning a $110 million upfront deal with Orano Med for the global rights to a neuroendocrine tumor treatment, Sanofi has returned with 300 million euros ($326 million) to set up a more | The new entity,
Sanofi and Orano Med partner on next-gen radioligand therapies
Sanofi has partnered with Orano Med, a subsidiary of Orano Group, to develop radioligand therapies for rare cancers. Sanofi will invest €300 million for a 16% stake in the venture. The collaboration focuses on using lead-212 isotopes to target difficult-to-treat cancers.
Press Release: Sanofi and Orano join forces to develop next-generation radioligand medicines
Sanofi and Orano join forces to develop next-generation radioligand medicinesParis, October 17, 2024. Sanofi and Orano Med, a subsidiary of the
Sanofi & Orano join forces to accelerate the development of develop next-generation radioligand medicines
Sanofi & Orano join forces to accelerate the development of develop next-generation radioligand medicines: Paris Friday, October 18, 2024, 10:00 Hrs [IST] Sanofi and Orano Med, a
BioSpace
4d
Sanofi Inks $326M Radiopharma Deal With Orano
Thursday’s agreement with Orano Med is the second in as many months. Sanofi in September made its first foray into the ...
4d
Sanofi, expanding in radiopharma, strikes a joint venture deal
The French drugmaker will invest 300 million euros into a new entity that will develop lead isotope-based therapies for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Liberty win first WNBA title
The Vessel to reopen
Oscar makes landfall
Helicopter hits radio tower
WWII code talker dies
Had multiple drugs in body?
Free OTC birth control plan
Anti-missile system in Israel
Albany State shooting
SCOTUS rejects Cohen suit
American activist Wair dies
Heckled in Australia
New Mexico flash flooding
Advance to World Series
Gold hits fresh high
NYC subway death trial
To name replacement in '26
Hezbollah assets targeted
Faces new lawsuits
Launches OneWeb mission
Oakland fire burns homes
To roll out AI agents in Nov
Austin visits Kyiv
Bitcoin nears $70,000
Urges support for Ukraine
Rock & Roll HOF '24 class
CVS workers strike
Ferry dock collapses in GA
Feedback